Delaware court enters USD 4 million judgment for Biohaven, Yale in trade secret case against RA Capital, Avilar

• Federal judge in Delaware entered judgment confirming a jury verdict against RA Capital Management, Avilar Therapeutics in a trade secret case tied to Yale’s MODA platform.
• Judgment formalized a combined USD 4 million award to Yale, Biohaven for willful, malicious misappropriation of the trade secret.
• RA Capital also found to have breached a 2019 confidentiality agreement with Yale, driving USD 2 million of the total award.
• Case stems from talks that ended in August 2019, followed by allegations RA Capital used shared technical information to build a competing program.
• Post-trial motions remain possible, leaving the final outcome subject to further court review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608251641PR_NEWS_USPR_____NE33676) on August 25, 2026, and is solely responsible for the information contained therein.